Idorsia announced
Half Year Results
for 2018
Are you looking for
more information
about our Phase 3
pipeline?
We hope you find everything you need to understand how Idorsia intends to achieve its ambitious goals. If you need any further support please don't hesitate to reach out to us.
Shareprice
Stay informed
Idorsia offers an electronic ‘Stay informed’ service. You will get the news sent to you.
Events
| Event | When |
| 9 Months 2018 Financial Results reporting | October 23, 2018 |
| Full-Year 2018 Financial Results reporting | February 7, 2019 |
| First Quarter 2019 Financial Results reporting | April 18, 2019 |
Financial information
Read all the latest financial information from Idorsia.
Our strategy
Find out more about the key priorities that management has set in order to develop Idorsia into one of Europe’s leading biopharmaceutical company.
Development pipeline
Idorsia has a diversified clinical development pipeline in multiple therapeutic areas, including central nervous system disorders, cardiovascular disorders, immunological disorders, and orphan diseases.
Corporate reports
Find out more about Idorsia.
Contact
Andrew C. Weiss
Senior Vice President, Head of Investor Relations and Corporate Communications